Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL991785 | 0.89 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL28163016 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1TSHR | |
| Trifluoromethanesulfonic Acid SCHEMBL27764749 | 0.87 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1TSHR | |
| Trifluoroacetic Acid SCHEMBL3634014 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR | |
| Trifluoroacetic Acid SCHEMBL19552101 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR | |
| Trifluoroacetic Acid SCHEMBL4163974 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR | |
| Trifluoroacetic Acid SCHEMBL9632138 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR | |
| Trifluoroacetic Acid SCHEMBL1525100 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR | |
| Trifluoroacetic Acid SCHEMBL60574 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR | |
| Trifluoroacetic Acid SCHEMBL19552090 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | disclosed |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | BACE1, APP, BACE2 | ALDH1A1 3005/4885L3MBTL1 2479/4885POLB 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.